Allergan, Inc.

David A Woodward

Ming Fai Chan

The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are encompassed by the following structure formula I: ##STR1## wherein wavy line attachments indicate either the alpha (a) or beta (b) configuration; hatched lines indicate a configuration, solid triangles are used to indicate b configuration, dashed bonds represent a double bond, or a single bond; n is 0, or an integer of from 1 to 3; X is NH.sub.2 or OR; R is hydrogen, R.sub.4 or a --(CO)R.sub.4 group; R.sub.1, R.sub.2, and R.sub.3 independently are hydroxyl, or --O(CO)R.sub.5 groups, wherein R.sub.4 and R.sub.5 independently stand for saturated or unsaturated acyclic hydrocarbon having from 1 to 20 carbon atoms, or --(CH.sub.2).sub.m R.sub.6 where m is 0-10 and R.sub.6 is an aliphatic, aromatic or heteroaromatic ring, R.sub.7 and R.sub.8 together are .dbd.O, or independently are hydrogen or alkyl of one to 6 carbon atoms or pharmaceutically acceptable salts thereof.

5-trans-prostaglandins of the F series and their use as ocular

The invention relates to a means of reducing or maintaining intraocular pressure, and, more particularly, to a method and composition for reducing or maintaining intraocular pressure involving the administration of a composition containing prostaglandin F.sub.3.alpha. in a pharmaceutically acceptable carrier.

Use of prostaglandin F.sub.3.alpha. as an ocular hypotensive agent

Disclosed are a method and composition for treating ocular hypertension. The compositions comprise prostaglandin-like 7-oxabicyclo derivatives which have been discovered to exhibit a pronounced intraocular pressure reducing effect, but with substantially reduced adverse side effects characteristic of the corresponding prostaglandin.

Growing community of inventors

El Toro, CA, United States of America

David A Woodward